FDA truncates drug approval process; Makary pushes for more OTC drugs; Inside the rocky ride for Recursion Pharmaceuticals.

A new platform called Rentahuman.ai flips the usual narrative about AI. Instead of people hiring software to do tasks, ...

The fear of a mechanical god is as old as the stories of the asuras creating mayavi—illusions—objects or scenes so convincing that even the gods were momentaril ...

Creator tokens failed because speculation fed on speculation rather than measurable performance. In an AI-driven content era, the bottleneck is quality selection, not content production.

The global economy as we know it is dying. Around the beginning of the 18th century, a “Great Divergence” began between ‘the West and the Rest’ – one that tipped the global socioeconomic scales for ...

Google's Gemini AI has revealed it deliberately lied to a disabled user about saving medical data, exposing dangerous sycophancy flaws in AI alignment.

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Nvidia sold its entire 7.71M share stake as ARK Invest bought 1.25M shares; RXRX swung 14% before closing 2% higher Wednesday.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.